Efficacy and safety of camrelizumab plus Lacticaseibacillus paracasei in the treatment of advanced esophageal squamous cell carcinoma: A single-arm, single-center, exploratory trial

Efficacy and safety of camrelizumab plus Lacticaseibacillus paracasei in the treatment of advanced esophageal squamous cell carcinoma: A single-arm, single-center, exploratory trial

Background: Esophageal cancer (EC) is the seventh most prevalent cancer and the sixth most common cause of cancer-related mortalities worldwide. Camrelizumab, a monoclonal antibody, has demonstrated moderate efficacy in esophageal squamous cell carcinoma (ESCC). Lactobacillus paracasei, a probiotic...

Full description

Saved in:
Bibliographic Details
Main Authors: Tengfei Zhang, Kang Cui, Xiaodan Liu, Yikai Han, Lin Li, Jinhui Xie, Xiangwen Dong, Yuhan Bao, Shengju Ren, Ziwen Lei, Pu Yu, Huan Zhao, Yabing Du, Wang Ma
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:Cancer Pathogenesis and Therapy
Subjects:
Camrelizumab
Esophageal squamous cell carcinoma
Lacticaseibacillus paracasei
Immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2949713224001058
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2949713224001058

Similar Items